This ongoing column is dedicated to providing information to our readers on managing legal risks associated with medical practice. We invite questions from our readers. The answers are provided by PRMS (www.prms.com), a manager of medical professional liability insurance programs with services that include risk management consultation and other resources offered to health care providers to help improve patient outcomes and reduce professional liability risk. The answers published in this column represent those of only one risk management consulting company. Other risk management consulting companies or insurance carriers might provide different advice, and readers should take this into consideration. The information in this column does not constitute legal advice. For legal advice, contact your personal attorney. Note: The information and recommendations in this article are applicable to physicians and other health care professionals so "clinician" is used to indicate all treatment team members.
{"title":"Risk Management: Fires, Floods, Hurricanes, Oh My! The Importance of Disaster Planning.","authors":"Akemini Kem Isang","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>This ongoing column is dedicated to providing information to our readers on managing legal risks associated with medical practice. We invite questions from our readers. The answers are provided by PRMS (www.prms.com), a manager of medical professional liability insurance programs with services that include risk management consultation and other resources offered to health care providers to help improve patient outcomes and reduce professional liability risk. The answers published in this column represent those of only one risk management consulting company. Other risk management consulting companies or insurance carriers might provide different advice, and readers should take this into consideration. The information in this column does not constitute legal advice. For legal advice, contact your personal attorney. Note: The information and recommendations in this article are applicable to physicians and other health care professionals so \"clinician\" is used to indicate all treatment team members.</p>","PeriodicalId":13635,"journal":{"name":"Innovations in clinical neuroscience","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11424069/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142346013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Waguih William IsHak, Ashley Meyer, Luiza Freire, Jayant Totlani, Nathalie Murphy, Sabrina Renteria, Mohamed Salem, Tiffany Chang, Rasha Abdelsalam, Rida Khan, Thomas Chandy, Thomas Parrish, Drew Hirsch, Bhumika Patel, Alexander J Steiner, Sarah Kim, Rebecca Hedrick, Robert N Pechnick, Itai Danovitch
Objective: This systematic review provides an overview of psychiatric medications in the late stages of development (Phase III clinical trials) as of June 1, 2024. It details the mechanisms of action, efficacy, dosing, and adverse effects of these medications.
Methods: We searched the PubMed database for Phase III studies of psychiatric medications published until June 1, 2024, using the keywords "psychiatric" OR "psychopharm*" AND "medic*" OR "pharm*". Our review encompassed medications currently undergoing Phase III clinical trials and those that have completed Phase III but are awaiting approval from the United States Food and Drug Administration (FDA). We independently analyzed the identified studies and reached a consensus on the medications to be included in this systematic review.
Results: As of June 1, 2024, a total of 89 pipeline drug trials were identified, including nine for schizophrenia, five for bipolar disorders, 25 for depressive disorders, 11 for anxiety disorders, five for post-traumatic stress disorder (PTSD), one for obsessive compulsive disorder (OCD), two for eating disorders, two for sleep-wake disorders, three for sexual dysfunctions, one for substance-related and addictive disorders, 22 for neurocognitive disorders, and three for neurodevelopmental disorders, specifically attention deficit hyperactivity disorder (ADHD).
Conclusion: The psychiatric medications in the pipeline as of June 1, 2024, demonstrate significant promise in treating psychiatric disorders.
{"title":"Overview of Psychiatric Medications in the Pipeline in Phase III Trials as of June 1, 2024: A Systematic Review.","authors":"Waguih William IsHak, Ashley Meyer, Luiza Freire, Jayant Totlani, Nathalie Murphy, Sabrina Renteria, Mohamed Salem, Tiffany Chang, Rasha Abdelsalam, Rida Khan, Thomas Chandy, Thomas Parrish, Drew Hirsch, Bhumika Patel, Alexander J Steiner, Sarah Kim, Rebecca Hedrick, Robert N Pechnick, Itai Danovitch","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>This systematic review provides an overview of psychiatric medications in the late stages of development (Phase III clinical trials) as of June 1, 2024. It details the mechanisms of action, efficacy, dosing, and adverse effects of these medications.</p><p><strong>Methods: </strong>We searched the PubMed database for Phase III studies of psychiatric medications published until June 1, 2024, using the keywords \"psychiatric\" OR \"psychopharm*\" AND \"medic*\" OR \"pharm*\". Our review encompassed medications currently undergoing Phase III clinical trials and those that have completed Phase III but are awaiting approval from the United States Food and Drug Administration (FDA). We independently analyzed the identified studies and reached a consensus on the medications to be included in this systematic review.</p><p><strong>Results: </strong>As of June 1, 2024, a total of 89 pipeline drug trials were identified, including nine for schizophrenia, five for bipolar disorders, 25 for depressive disorders, 11 for anxiety disorders, five for post-traumatic stress disorder (PTSD), one for obsessive compulsive disorder (OCD), two for eating disorders, two for sleep-wake disorders, three for sexual dysfunctions, one for substance-related and addictive disorders, 22 for neurocognitive disorders, and three for neurodevelopmental disorders, specifically attention deficit hyperactivity disorder (ADHD).</p><p><strong>Conclusion: </strong>The psychiatric medications in the pipeline as of June 1, 2024, demonstrate significant promise in treating psychiatric disorders.</p>","PeriodicalId":13635,"journal":{"name":"Innovations in clinical neuroscience","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11424068/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142346012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Activation of the serotonergic neurotransmission is a double-edged sword in the treatment of burning mouth syndrome.","authors":"Takahiko Nagamine","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":13635,"journal":{"name":"Innovations in clinical neuroscience","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11424071/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142346009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Andrew B Correll, Terry L Correll, Matthew C Correll
Bibliotherapy, a relatively underutilized lifestyle intervention in psychotherapy, is a unique cost-effective avenue of treatment that empowers patients by integrating therapeutic reading into their treatment plan. This approach strategically uses empirically validated cognitive-behavioral and self-help literature to facilitate the application of therapeutic topics outside of psychotherapy sessions. Bibliotherapy's range of administration styles highlights its potential as an adjunct to medication, psychotherapy, and/or healthy lifestyle interventions in a comprehensive treatment plan. Most meta-analyses conducted so far regarding bibliotherapy in a clinical setting consist of studies that use minimal patient interaction via short phone calls or emails. Despite this, meta-analyses show medium-to-large effect sizes that are comparable to traditional psychotherapy modalities for common disorders, most notably depression. This article explores the practical implementation of bibliotherapy research via an example psychotherapy session with a patient who has a diagnosis of major depressive disorder (MDD). An evidence-based reading list is proposed alongside a decision tree and actionable clinical insights for the effective implementation of bibliotherapy.
{"title":"Literary Prescriptions: Applying Bibliotherapy in a Psychotherapeutic Context.","authors":"Andrew B Correll, Terry L Correll, Matthew C Correll","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Bibliotherapy, a relatively underutilized lifestyle intervention in psychotherapy, is a unique cost-effective avenue of treatment that empowers patients by integrating therapeutic reading into their treatment plan. This approach strategically uses empirically validated cognitive-behavioral and self-help literature to facilitate the application of therapeutic topics outside of psychotherapy sessions. Bibliotherapy's range of administration styles highlights its potential as an adjunct to medication, psychotherapy, and/or healthy lifestyle interventions in a comprehensive treatment plan. Most meta-analyses conducted so far regarding bibliotherapy in a clinical setting consist of studies that use minimal patient interaction via short phone calls or emails. Despite this, meta-analyses show medium-to-large effect sizes that are comparable to traditional psychotherapy modalities for common disorders, most notably depression. This article explores the practical implementation of bibliotherapy research via an example psychotherapy session with a patient who has a diagnosis of major depressive disorder (MDD). An evidence-based reading list is proposed alongside a decision tree and actionable clinical insights for the effective implementation of bibliotherapy.</p>","PeriodicalId":13635,"journal":{"name":"Innovations in clinical neuroscience","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11424070/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142346010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: Intellectual disability (ID) is considered one of the most common human disorders characterized by significant deficits in cognition and functional and adaptive skills. The aims of this study were to describe the demographic and clinical features of a group of Moroccan individuals with ID living in the Tangier-Tetouan region.
Design: This was a retro-prospective and descriptive exploratory monocentric study realized between November 2020 and August 2023. A total of 109 patients with ID were included. They were selected at four mental health centers in the Tangier-Tetouan region. Our data were treated and analyzed using the IBM SPSS version 26.
Results: A male predominance of patients with ID was observed in our series (54.4% male vs. 42.6% female). The male-to-female ratio was 1.34. The mean±standard deviation (SD) age of our patients was 11.75±4.87 years, ranging from 1 to 35 years. The mean ages of mothers and fathers at the births of their children with ID were 28.36 and 35.6 years, respectively. Many co-occurring medical conditions were noted in our data (speech delay: 20.5%, concentration problems: 15.1%, hyperactivity: 11.1%, ambulation difficulties: 8.8%, aggressiveness: 8%, vision problems: 6.3%, epileptic seizures: 4%). The consanguinity rate was 26.9 percent.
Conclusion: ID associated with genetic causes was significantly correlated with the consanguinity rate in the Moroccan population.
{"title":"Study of Clinical Characteristics of Intellectual Disability in Morocco.","authors":"Houda Bekkari, Yousra Benmakhlouf, Naima Ghailani Nourouti, Amina Barakat, Mohcine Bennani Mechita","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>Intellectual disability (ID) is considered one of the most common human disorders characterized by significant deficits in cognition and functional and adaptive skills. The aims of this study were to describe the demographic and clinical features of a group of Moroccan individuals with ID living in the Tangier-Tetouan region.</p><p><strong>Design: </strong>This was a retro-prospective and descriptive exploratory monocentric study realized between November 2020 and August 2023. A total of 109 patients with ID were included. They were selected at four mental health centers in the Tangier-Tetouan region. Our data were treated and analyzed using the IBM SPSS version 26.</p><p><strong>Results: </strong>A male predominance of patients with ID was observed in our series (54.4% male vs. 42.6% female). The male-to-female ratio was 1.34. The mean±standard deviation (SD) age of our patients was 11.75±4.87 years, ranging from 1 to 35 years. The mean ages of mothers and fathers at the births of their children with ID were 28.36 and 35.6 years, respectively. Many co-occurring medical conditions were noted in our data (speech delay: 20.5%, concentration problems: 15.1%, hyperactivity: 11.1%, ambulation difficulties: 8.8%, aggressiveness: 8%, vision problems: 6.3%, epileptic seizures: 4%). The consanguinity rate was 26.9 percent.</p><p><strong>Conclusion: </strong>ID associated with genetic causes was significantly correlated with the consanguinity rate in the Moroccan population.</p>","PeriodicalId":13635,"journal":{"name":"Innovations in clinical neuroscience","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11424067/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142346014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Uzma Ilyas, Sabeela Saher, Ayesha Ahmad Khan, Anam Shahid, Zarmeen Tariq
Objective: This systematic review aimed to identify the effect of obsessive compulsive disorder (OCD) on cognitive processes, such as memory, executive functioning, and cognitive flexibility, among the adult populations of Asian countries.
Methods: The systematic review progressed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. It is comprised of articles sourced from Asian countries published from 2018 to 2022, and literature about deficits in memory, executive functioning, and cognitive flexibility in the OCD population was gathered from five electronic databases, including Google Scholar, PubMed, Research Gate, Science Direct, and Wiley Online Library. Full-text impact factor articles in the English language were considered in this study.
Results: This study screened 44 articles; five were included based on the eligibility criteria for the present systematic review. Four articles found cognitive deficits in the domains of executive functioning, memory, and cognitive flexibility among patients with OCD, whereas results of one article showed normal cognitive performance of the patients. Demographic variables showed no significant differences between patients with OCD and healthy controls.
Conclusion: This systematic review indicated deficits specifically in the cognitive functioning and flexibility of patients with OCD. Despite a noticeable prevalence of OCD in Asian countries, the literature on correlates and neurological functioning is scarce. Further studies are required to examine the effects on the larger population and provide knowledge in those countries and areas where people are suffering because of minimal knowledge regarding OCD.
{"title":"Neuropsychological Functioning Among Patients with OCD in Asian Countries: A Systematic Review.","authors":"Uzma Ilyas, Sabeela Saher, Ayesha Ahmad Khan, Anam Shahid, Zarmeen Tariq","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>This systematic review aimed to identify the effect of obsessive compulsive disorder (OCD) on cognitive processes, such as memory, executive functioning, and cognitive flexibility, among the adult populations of Asian countries.</p><p><strong>Methods: </strong>The systematic review progressed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. It is comprised of articles sourced from Asian countries published from 2018 to 2022, and literature about deficits in memory, executive functioning, and cognitive flexibility in the OCD population was gathered from five electronic databases, including Google Scholar, PubMed, Research Gate, Science Direct, and Wiley Online Library. Full-text impact factor articles in the English language were considered in this study.</p><p><strong>Results: </strong>This study screened 44 articles; five were included based on the eligibility criteria for the present systematic review. Four articles found cognitive deficits in the domains of executive functioning, memory, and cognitive flexibility among patients with OCD, whereas results of one article showed normal cognitive performance of the patients. Demographic variables showed no significant differences between patients with OCD and healthy controls.</p><p><strong>Conclusion: </strong>This systematic review indicated deficits specifically in the cognitive functioning and flexibility of patients with OCD. Despite a noticeable prevalence of OCD in Asian countries, the literature on correlates and neurological functioning is scarce. Further studies are required to examine the effects on the larger population and provide knowledge in those countries and areas where people are suffering because of minimal knowledge regarding OCD.</p>","PeriodicalId":13635,"journal":{"name":"Innovations in clinical neuroscience","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11424072/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142346011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Response to \"ChatGPT and Transcranial Direct Current Stimulation for Chronic Pain\".","authors":"Hinpetch Daungsupawong, Viroj Wiwanitkit","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":13635,"journal":{"name":"Innovations in clinical neuroscience","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11208012/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141474624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Responding to Commentary: Addressing Points Raised in the Correspondence About \"ChatGPT and Transcranial Direct Current Stimulation for Chronic Pain\".","authors":"Edson Silva-Filho, Rodrigo Pegado","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":13635,"journal":{"name":"Innovations in clinical neuroscience","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11208013/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141474622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Carolyn O'Donnell, Tammie Lee Demler, Eileen Trigoboff, Claudia Lee
Introduction: Well-known adverse events of antipsychotics are movement disorders, or extrapyramidal symptoms, such as drug-induced parkinsonism and tardive dyskinesia.
Objective: With new evidence suggesting a link between low high-density lipoprotein cholesterol (HDL-C) and risk of Parkinson's disease, this study sought to investigate if that link also translated to patients taking antipsychotics with low HDL-C and an increased risk for developing a movement disorder.
Design: Adult patients (n=89) at an inpatient state psychiatric facility taking at least one antipsychotic with at least one HDL-C level were assessed for signs of a movement disorder through their history and physical, progress notes, and Abnormal Involuntary Movement Scale (AIMS) score.
Results: There was no statistical significance when comparing a patient's movement disorder, AIMS scores, and HDL-C levels to suggest that the HDL-C level influenced a patient's movement disorder.
Conclusion: This study did not show a correlation between HDL-C levels and a patient's risk of developing a movement disorder while taking an antipsychotic.
{"title":"The Impact of High-density Lipoprotein Cholesterol (HDL-C) Levels and Risk of Movement Disorders in Patients Taking Antipsychotics.","authors":"Carolyn O'Donnell, Tammie Lee Demler, Eileen Trigoboff, Claudia Lee","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Introduction: </strong>Well-known adverse events of antipsychotics are movement disorders, or extrapyramidal symptoms, such as drug-induced parkinsonism and tardive dyskinesia.</p><p><strong>Objective: </strong>With new evidence suggesting a link between low high-density lipoprotein cholesterol (HDL-C) and risk of Parkinson's disease, this study sought to investigate if that link also translated to patients taking antipsychotics with low HDL-C and an increased risk for developing a movement disorder.</p><p><strong>Design: </strong>Adult patients (n=89) at an inpatient state psychiatric facility taking at least one antipsychotic with at least one HDL-C level were assessed for signs of a movement disorder through their history and physical, progress notes, and Abnormal Involuntary Movement Scale (AIMS) score.</p><p><strong>Results: </strong>There was no statistical significance when comparing a patient's movement disorder, AIMS scores, and HDL-C levels to suggest that the HDL-C level influenced a patient's movement disorder.</p><p><strong>Conclusion: </strong>This study did not show a correlation between HDL-C levels and a patient's risk of developing a movement disorder while taking an antipsychotic.</p>","PeriodicalId":13635,"journal":{"name":"Innovations in clinical neuroscience","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11208005/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141467781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Response to \"Clinical Outcome Assessment Instruments in Schizophrenia: A Scoping Literature Review with a Focus on the Potential of Patient-reported Outcomes\".","authors":"Sílvia Zaragoza Domingo","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":13635,"journal":{"name":"Innovations in clinical neuroscience","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11208006/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141474625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}